SAR449336 / Blueprint Medicines, Sanofi - LARVOL DELTA

A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress) (ESMO 2026) - No abstract available

Clinical • First-in-human • Metastases • P1/2 data • Oncology • Solid Tumor • KRAS

Translational Activity of the Pan-KRAS Inhibitor SAR449336 Across KRAS-Driven Preclinical Tumor Models (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Oncology • KRAS

SAR449336: A Potent, Orally Bioavailable, HRAS and NRAS Sparing, Small Molecule Pan-KRAS Inhibitor With Broad Biochemical and Cellular Activity (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Oncology • HRAS • KRAS

A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress) (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Clinical • First-in-human • Metastases • P1/2 data • Oncology • Solid Tumor • KRAS